Loading
A phase 2 trial of MR-guided adaptive radiotherapy in Rectal cancer, run by Fudan University, now recruiting.
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT06840665 by Fudan University, with 46 participants planned, started 2024-08-13 and due to reach its primary completion in 2026-08-12. Interventions recorded: PD-1 antibody, Oxaliplatin, Capecitabine. Conditions recorded: Locally Advanced Rectal Cancer.
Linked to the technology MR-guided adaptive radiotherapy because the registry's title names it ("mr guided adaptive radiotherapy") and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.
Shares MR-guided adaptive radiotherapy, Rectal cancer and the tag pipeline.
Shares Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Toripalimab, Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Capecitabine, Rectal cancer and the tag pipeline.